Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Personlig medicin i præ-diabetes og tidlig type 2-diabetes (PREDICT)

30. september 2026 opdateret af: Garvan Institute of Medical Research

Personalised Medicine in Prediabetes - Towards Preventing Diabetes in Individuals at Risk

Prediabetes is a common condition in overweight individuals affecting approximately 35% of American adults and 30% of Australian adults. Like diabetes, prediabetes is a serious risk factor for cardiovascular disease, eye, kidney and liver disease, and some types of cancer.

Appropriate blood glucose control is crucial in preventing pre-diabetes complications and onset of diabetes, yet clinical practice, backed by randomised trials, reports that many patients treated with standard dietary guidelines or with the first-line treatment of diabetes patients, metformin, do not improve blood glucose control sufficiently.

The overarching goal of the present project is to improve the efficacy of metformin mono-therapy in pre-diabetes and early type 2 diabetes.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Prediabetes is common in overweight and obese individuals and, as with frank diabetes, it is a risk factor for cardiovascular disease, cognitive dysfunction, fatty liver, kidney, ophthalmic, renal and neuropathic disease, and cancer.

Effective management of dysglycemia in pre-diabetes and diabetes and prevention of diabetes in individuals at risk reduce the risk of organ damage and associated co-morbidities and improves the affected individuals' quality of life.

Metformin, an oral biguanide, is the first-line treatment of newly-diagnosed type 2 diabetes patients, and the pharmacological choice for preventing diabetes in individuals with pre-diabetes. Metformin is an ideal medication to initiate for diabetes prevention, due to its excellent safety profile (lack of hypoglycemia), neutral to marginally beneficial effect on body weight, evidence of cardio-protection, and low cost. However, clinical practice, backed by randomised clinical trials, suggests that metformin mono-therapy fails to achieve glycemic goals in 20-40% of type 2 diabetes patients and to prevent diabetes in approximately 20% of individuals with pre-diabetes.

While the mode of action of metformin is still being investigated, the liver and the gastrointestinal tract are thought to be the main targets responsible for the improvement in glycemia. An increasing body of evidence suggests that the gut microbiota play an important role in obesity, prediabetes and diabetes, and alterations in gut microbial composition have been described in individuals with type 2 diabetes and pre-diabetes. Interestingly, metformin-treated diabetes patients have a "healthier" gut microbial composition compared with treatment-naïve diabetes patients, and changes in gut microbial composition with metformin treatment has been suggested to contribute to the therapeutic effect of the medication.

Randomised, clinical study with parallel assignment and single-masking will be performed in treatment-naïve individuals with pre-diabetes or early type 2 diabetes (diagnosed in the last 6 months) aiming to compare the effect of metformin (extended release [XR]) 1500 mg/d administered with personalized diet (based on the Weizmann Institute Personalized Nutrition Project) or administered with a healthy (low fat) diet.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

138

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • New South Wales
      • Sydney, New South Wales, Australien, 2010
        • Garvan Institute of Medical Research

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

20 år til 70 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion criteria:

  • Prediabetes or early-stage type 2 diabetes according to the American Diabetes Association (2019) diagnostic criteria, with HbA1c ≤8.0% (64 mmol/mol).
  • Women of childbearing potential willing to take precautions to avoid pregnancy throughout the study and for 3 months after the end of treatment.
  • Willingness to provide written informed consent and willingness to participate and comply with the study.

Exclusion Criteria:

  • Females planning a pregnancy during the course of the research or 3 months after completion of the research project. Females who breastfeed.
  • Patients with type 1 diabetes, chronically active inflammatory disease, neoplastic disease in the previous 3 years, chronic gastrointestinal disorders, including inflammatory bowel disease or celiac.
  • Liver enzymes ALT and/or AST>3-times normal range limit.
  • Abnormal renal function as measured by (eGFR<45 mL/min/1.73m^2).
  • Individuals with a history of a psychological illness or condition that may interfere with the individual's ability to understand the requirements of the study.
  • Normo-glycaemia.
  • HbA1c>8.0%
  • Cardiovascular event in the previous 6 months.
  • Current or recent (within 24 months) treatment with a glucose lowering medication (i.e. GLP-1 receptor agonist, SGLT2 inhibitor, thiazolidinedione, sulfonylurea, DPP-4 inhibitor or insulin).
  • Current or recent (within 3 months) treatment with metformin.
  • Treatment with an oral steroid.
  • Treatment with antibiotics in the last 3 months.
  • Treatment with immunosuppressive medications.
  • Treatment with medications known to interact with metformin, including cimetidine, vitamin K antagonists and nifedipine.
  • Substance abuse.
  • Participants who had received an investigational new drug within the last 6 months.
  • Participants involved in another clinical study.
  • Participants who actively lose weight.
  • Participants who had a bariatric surgery.
  • Any reason the Investigator believes the participant is not likely to be adherent to the study treatment and protocol, including non-adherence to run-in.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Metformin + Healthy diet

Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet

Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet

Andre navne:
  • Metformin + Sund (fedtfattig) kost
Aktiv komparator: Metformin + Personalized diet

Metformin (1500 mg/d, Extended Release) + Personalized diet based on an algorithm developed at the Weizmann Institute of Science (Zeevi et al, Cell 2015)

Metformin (1500 mg/d, Extended Release) + Algorithm-based personalized diet

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Mean change in glycated haemoglobin (HbA1C, %) from baseline
Tidsramme: 6 months

Difference in the reduction of HbA1C between the groups

6 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Total daily time of interstitial glucose levels below 7.8 mmol/L (140 mg/dL)
Tidsramme: 6 months

Difference in the time (minutes) per day with interstitial glucose measured below 7.8 mmol/L (140 mg/dL) between the groups

6 months
Glycaemic variability
Tidsramme: 6 months

Difference in the glycaemic variability as derived from CGM between the groups

6 months
Body weight
Tidsramme: 6 months

Difference in the magnitude of weight loss between the groups

6 months
Body fat mass
Tidsramme: 6 months

Difference in body fat mass composition as assessed using dual-energy X-ray absorptiometry (DXA) between the groups

6 months
Abdominal visceral fat volume
Tidsramme: 6 months

Difference in the abdominal visceral fat volume as assessed using DXA between the groups

6 months
Serum low-density lipoprotein (LDL)-cholesterol concentration
Tidsramme: 6 months

Difference in serum LDL-cholesterol between the groups

6 months
Serum high-density lipoprotein (HDL)-cholesterol concentration
Tidsramme: 6 months

Difference in serum HDL-cholesterol concentration between the groups

6 months
Serum triglycerides concentration
Tidsramme: 6 months

Difference in serum triglycerides between the groups

6 months
Blood pressure
Tidsramme: 6 months

Difference in diastolic and systolic blood pressure between the groups

6 months
Liver fat
Tidsramme: 6 months

Difference in liver fat measured by the Fibroscan's controlled attenuation parameter (CAP) function between the groups

6 months

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Gut microbiome (exploratory)
Tidsramme: 6 months

Difference in gut microbiome features between the groups

6 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Dorit Samocha-Bonet, PhD, Garvan Institute of Medical Research
  • Ledende efterforsker: Jerry Greenfield, MD, PhD, Garvan Institute of Medical Research
  • Ledende efterforsker: Eran Elinav, MD, PhD, Weizmann Institute of Science
  • Ledende efterforsker: Eran Segal, PhD, Weizmann Institute of Science

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

5. juni 2018

Primær færdiggørelse (Faktiske)

15. december 2023

Studieafslutning (Faktiske)

23. juli 2024

Datoer for studieregistrering

Først indsendt

5. juni 2018

Først indsendt, der opfyldte QC-kriterier

5. juni 2018

Først opslået (Faktiske)

15. juni 2018

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

30. september 2026

Sidst verificeret

1. august 2023

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • SVH 17/080

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .